2014-03-20 – Page 3 – China Stock Advice

UTSI [UTSTARCOM] 6-K: UTStarcom Reports Unaudited Financial Results for the Fourth

[UTStarcom Reports Unaudited Financial Results for the Fourth Quarter and Full Year 2013 - Significantly Expanded Global Customer Base- - Launched a Number of Innovative New Broadband and SDN Products- - Further Streamlined Operations and Significantly Reduced Operating Expenses- Hong Kong, March 20, 2014 UTStarcom (UTStarcom or the Company) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today reported its] [UTStarcom Holdings Corp. Fourth Quarter and Full Year 2013 Results NASDAQ: UTSI March 20, 2014 Mr. William Wong, CEO Mr. James Lu, President Mr. Robert Pu, CFO 1 3 Earnings Call Agenda Introduction Update on Operating Progress Update on Shareholder Value Initiatives Our Go-forward Strategy Global Sales & Marketing Growth Plan and Recent Customer Wins Overview of Fourth Quarter and] [FORM 6-K UTSTARCOM HOLDINGS CORP. Unit 7, Level 23, One Island East, 18 Westlands Road, Hong Kong Form 20-F x Form 40-F o o o Yes o No x]

By info| 2016-03-27T20:00:49+00:00 March 20th, 2014|Categories: Chinese Stocks, UTSI, Webplus ver|Tags: 0001030471, 2014-03-20, 3669, 6-K, COMMUNICATIONS EQUIPMENT, NEC, UTSI|0 Comments

KNDI [Kandi Technologies] 8-K/A: (Original Filing)

[March 20, 2014 Board of Directors Gentlemen: Company Shares Common Stock We have acted as legal counsel to Kandi Technologies Group, Inc., a Delaware corporation (the Purchase Agreement Registration Statement Commission Base Prospectus Prospectus Supplement Securities Act Certificate of Incorporation Bylaws Board of Directors Based upon the foregoing and subject to the assumptions, limitations and exceptions set forth herein,] [FORM 8-K AMENDMENT NO. 1) CURRENT REPORT Date of Report (Date of earliest event reported): March 19, 2014 KANDI TECHNOLOGIES GROUP, INC. Delaware 001-33997 90-0363723 (State of Incorporation) (IRS Employer Identification) Jinhua City Industrial Zone Item 1.01 Entry into a Material Definitive Agreement. $ , 5.1 Opinion of McKenna Long & Aldridge LLP 23.1 KANDI TECHNOLOGIES GROUP, INC. Hu Xiaoming]

By info| 2016-03-13T09:28:43+00:00 March 20th, 2014|Categories: Chinese Stocks, KNDI, SEC Original|Tags: 0001316517, 2014-03-20, 3711, 8-K.A, KNDI, MOTOR VEHICLES and PASSENGER CAR BODIES|0 Comments

CPHI [CHINA PHARMA] 10-K: (Original Filing)

[FORM 10-K x For the fiscal year ended December 31, 2013 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Yingwen Zhang, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Baowen Dong, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD30,667 respectively as of December 31, 2013. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui and] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 20, 2014 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2013 appearing] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2012 appearing] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 President and Chief Executive Officer EX-32.1 10 ex321.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 (principal financial officer and principal accounting officer) EX-32.2 11 ex322.htm]

By info| 2016-03-28T19:41:44+00:00 March 20th, 2014|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-K, 2014-03-20, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

KNDI [Kandi Technologies] 8-K/A: March 20, 2014 Board of Directors Gentlemen: Company

[March 20, 2014 Board of Directors Gentlemen: Company Shares Common Stock We have acted as legal counsel to Kandi Technologies Group, Inc., a Delaware corporation (the Purchase Agreement Registration Statement Commission Base Prospectus Prospectus Supplement Securities Act Certificate of Incorporation Bylaws Board of Directors Based upon the foregoing and subject to the assumptions, limitations and exceptions set forth herein,] [FORM 8-K AMENDMENT NO. 1) CURRENT REPORT Date of Report (Date of earliest event reported): March 19, 2014 KANDI TECHNOLOGIES GROUP, INC. Delaware 001-33997 90-0363723 (State of Incorporation) (IRS Employer Identification) Jinhua City Industrial Zone Item 1.01 Entry into a Material Definitive Agreement. $ , 5.1 Opinion of McKenna Long & Aldridge LLP 23.1 KANDI TECHNOLOGIES GROUP, INC. Hu Xiaoming]

By info| 2016-03-13T09:29:56+00:00 March 20th, 2014|Categories: Chinese Stocks, KNDI, Webplus ver|Tags: 0001316517, 2014-03-20, 3711, 8-K.A, KNDI, MOTOR VEHICLES and PASSENGER CAR BODIES|0 Comments

CPHI [CHINA PHARMA] 10-K: FORM 10-K x For the fiscal year ended

[FORM 10-K x For the fiscal year ended December 31, 2013 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Yingwen Zhang, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Baowen Dong, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD30,667 respectively as of December 31, 2013. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui and] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 20, 2014 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2013 appearing] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2012 appearing] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 President and Chief Executive Officer EX-32.1 10 ex321.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 (principal financial officer and principal accounting officer) EX-32.2 11 ex322.htm]